Here are the 10-K annual reports from GridAI Technologies Corp. (GRDX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GRDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRDX filings page.
GridAI Technologies Corp. filed its annual report outlining a strategic shift into AI-focused energy orchestration software while retaining its Adrulipase drug program. The company acquired Grid AI Corp. and 75% of AMPX, rebranded from Entero Therapeutics, and now centers on software for AI data centers and legacy biopharma R&D.
Grid AI’s platforms are early stage with minimal revenue and no commercial deployment yet for its AI data center solution. Adrulipase remains the main drug asset but had no active trials in 2025. At December 31, 2025, cash was about $0.9 million against an accumulated deficit of roughly $208.8 million, and auditors raised substantial doubt about continuing as a going concern.
The company defaulted on an 18% revolving loan and is exploring strategic alternatives, including potential merger, sale, wind-down or bankruptcy, while also managing past and current Nasdaq listing compliance issues. Only two parent-level employees remain, underscoring the scale-back as GridAI pursues a high-risk turnaround around its AI energy orchestration platform.